Article Text

Download PDFPDF
The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.
  1. W J Morrow,
  2. D J Williams,
  3. C Ferec,
  4. R Casburn-Budd,
  5. D A Isenberg,
  6. E Paice,
  7. M L Snaith,
  8. P Youinou,
  9. P Le Goff


    Plasma samples from 44 patients with systemic lupus erythematosus (SLE) and 43 with rheumatoid arthritis (RA) were assayed for C3d, a breakdown product of the third component of complement (C3), which was also measured in parallel. Levels of C3d varied in direct proportion with disease activity in RA, whereas C3 showed little change. Although C3d values also increased with worsening clinical condition in SLE, this trend was not considered to be sufficiently clear to be useful and did not provide any advantage over the routinely performed C3 assay.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.